ArticleDevice2025
Public Perceptions of Neurotechnologies Used to Target Mood, Memory, and Motor Symptoms.
Article in Device, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Implantable Neuromodulation Devices in Psychiatry: Human Fidelity and Implementation Challenges.The American journal of psychiatry · 2026Article
- Engaging patient communities in intracranial neuroscience research.medRxiv : the preprint server for health sciences · 2026Article
- Deep brain stimulation clinical trials: a framework to accelerate recruitment, retention, and technology translation.Frontiers in human neuroscience · 2026Article
Corrections and comments
- Update of
Authors and funding
7 authors.
Funding
Abstract
Public attitudes toward four neurotechnologies for treating three types of brain disorders (mood, motor, and memory) vary on a range of metrics such as perceived risk, invasiveness, and likelihood of use. In a survey of 1,052 U.S. participants, deep brain stimulation (DBS) was seen as the most invasive and risky among the surveyed methods, involving the greatest perceived change to the person and the least likely to be used personally. Non-surgical options like transcranial magnetic stimulation (TMS) and pills were viewed as more acceptable. Devices targeting motor symptoms were rated as more beneficial and acceptable than those for mood or memory. These findings highlight barriers to adoption and the need to address public perceptions, ensure patients are informed, and promote ethical implementation of these technologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.